↓ Cooling
Business
🔮 fades
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead Pharmaceuticals stock surges 24.4% following positive late-stage clinical data for its lipid-lowering drug, Redemplo.